Entire Transcript in Adobe Acrobat Format - National Reference ...

87
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a research although there is nothing to say that it could
not be attempted in a clinical situation to get some sort
of layered approach. It is not really a very complicated
thing. It looks complicated and it sounds complicated, and
in practice it has not -- we have not had anyone refuse
anything or have any problems with it and it has been in
effect for a couple of years now.
DR. MURRAY: Steve?
DR. HOLTZMAN: I would like to just try to
focus then if I can on where I think -- I would like to
focus if possible on where I think your recommendations are
similar to what we have said and where they are different,
and maybe try to elicit the differences in thinking.
With respect to the prospectively collected
samples I believe we are very, very similar in our thinking
at least with respect to those which are collected in a
research context leaving open whether we think those
collected in a clinical context can have such a robust
consent process.
With respect to the extant samples you have
focused on the sample being anonymous or anonymized versus
our focus on the research being conducted anonymously or
encrypted, what you call identifiable using the ASHG
categories.